Ori Biotech featured on the Life Sciences Knowledge Hub with David McLelland

Jason C. Foster discusses the importance of the work Ori is doing to address barriers to access for cell and gene therapies, highlighting the urgent need for innovation in the CGT manufacturing technology space.

Ori has developed a proprietary, flexible manufacturing platform that closes, automates, and standardizes CGT manufacturing allowing therapeutics developers to bring products to market at commercial scale. The promise of the full stack Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality, and decrease costs by combining hardware, software, and data services, enabling broader access to these lifesaving treatments.

More on: chemicalsknowledgehub.com

Watch full interview: www.youtube.com/watch?v=T1UW0E-0ot0

Related Articles

The Medicine Maker
Ori Biotech News

New article from The Medicine Maker: Ori Biotech CEO Jason C Foster discusses the impact of BREXIT on CGT manufacturing

Ori Biotech Team Members At Work

Learn more about the team working to enable patient access to lifesaving treatments

Read more
Ori and G-CON Manufacturing Partnership
Ori Biotech Press Releases

G-CON Manufacturing and Ori Biotech Collaborate to Develop an Integrated Modular Manufacturing Platform for Cell and Gene Therapy Developers

Read more